GNA NOW - new medicines for Gram-negative bacteria

Antimicrobial resistance (AMR) is a major threat to public health, and so-called Gram-negative bacteria are particularly diificult to treat, as they are encased in a tough outer membrane which effectively stops many antibiotics from killing it.

The GNA NOW project aims to develop new antibiotics by testing different drug candidates to enhance the overall pipeline of medicines for patients with infections caused by these bacteria.

In GNA NOW grit Scientific Data Management Platform is used as the central data management platform where participants store and share data from the programs.

About IMI AMR GNA NOW

GNA NOW (Gram-Negative Antibacterials NOW Consortium) aims to develop completely novel compounds derived from previously unknown natural compounds with new modes of action.

From the start three programs were run in parallel, each focusing on a different drug candidate with an innovative mode of action. Two have been terminated due to unmet criteria and one (NOSO502) has advanced to Phase 1. In 2023 a fourth program became part of GNA NOW.

GNA NOW is part of the AMR Accelerator, an IMI program that comprises 9 projects with the shared goal of progressing the development of new medicines to treat or prevent resistant bacterial infections.

The total funding of 21.629.466 € is provided by EU and EFPIA. The project runs from 2019-2025.

Participants:

The project consortium consist of 11 participants ranging from EFPIA members, research organisations and universities, SMEs, and thirds parties.

A central scientific data store

In the GNA NOW project grit serves as a central scientific data store where research data are loaded using the data templates defined in COMBINE - another project under AMR Acceerator.

The data are stored in accordance with the FAIR principles and the structured data are used for creating knowledge graphs.